Biotech · Public company · Boston, MA, US
Compass Therapeutics, Inc.
Ticker CMPX · SEC CIK 0001738021
Track this companyFree. Adds Compass Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials86 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline8
- CTX-009Phase 3 · Biliary Tract CancerClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Biliary Tract CancerClinicalTrials.gov · fetched Nov 12, 2026
- CTX-009Phase 2 · Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- CTX-471Phase 2 · Neuroendocrine NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- CTX-10726Phase 1 · Gastroesophageal Cancer (GC)ClinicalTrials.gov · fetched Nov 12, 2026
- CTX-471Phase 1 · Locally Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CTX-8371Phase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab (KEYTRUDA®)Phase 1 · Locally Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal CancerPHASE2 · NOT_YET_RECRUITING · started Dec 31, 2026ClinicalTrials.gov NCT07662031 · fetched Nov 12, 2026
- Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine NeoplasmsPHASE2 · RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07684170 · fetched Nov 12, 2026
- Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent GlioblastomaPHASE1_PHASE2 · RECRUITING · started Jun 16, 2026ClinicalTrials.gov NCT07392957 · fetched Nov 12, 2026
- A Phase 1 Study of the Safety and Tolerability of CTX-10726PHASE1 · RECRUITING · started May 28, 2026ClinicalTrials.gov NCT07419841 · fetched Nov 12, 2026
- A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesPHASE1 · RECRUITING · started Mar 19, 2024ClinicalTrials.gov NCT06150664 · fetched Nov 12, 2026
- A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)PHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Jan 9, 2023ClinicalTrials.gov NCT05506943 · fetched Nov 12, 2026
- A Study of CTX-009 in Adult Patients With Metastatic Colorectal CancerPHASE2 · COMPLETED · started Dec 8, 2022ClinicalTrials.gov NCT05513742 · fetched Nov 12, 2026
- Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced MalignanciesPHASE1 · TERMINATED · started May 17, 2019ClinicalTrials.gov NCT03881488 · fetched Nov 12, 2026
SEC filings12
- 10-Q · FORM 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 22, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 1, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 23, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 11, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Apr 27, 2026 · fetched Nov 12, 2026
- 10-K · FORM 10-KSEC EDGAR · filed Mar 5, 2026 · fetched Nov 12, 2026